Dr. Reddy’s Laboratories shares in focus after acquiring India trademarks for two HRT drugs for $32 million
Dr. Reddy’s Laboratories shares in focus after million'>acquiring India trademarks for two HRT drugs for $32 million is drawing significant interest across the industry.
Dr. Reddy's Laboratories is set to attract investor attention after acquiring the India trademarks for specialty brands Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for USD 32.15 million. This domestic acquisition significantly strengthens Dr. Reddy's gynecology portfolio and marks its entry into the Hormone Replacement Therapy segment in India.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Trump climate health rollback likely to hit poor, minority areas: experts
- KP minister reviews progress on major water, sanitation schemes
- Lucid slashes hundreds of East Bay jobs as electric car firm fights red ink
- Soccer-Forest sack manager Dyche after four months in charge
Source: Original →